J&J submits new FDA application for Nucynta ER
TITUSVILLE, N.J. — A Johnson & Johnson subsidiary has sent a regulatory application to the Food and Drug Administration seeking approval for one of its drugs in treating diabetes-related pain.
J&J Pharmaceutical Research & Development announced Monday the submission of its supplemental new drug application for Nucynta ER (tapentadol) extended-release tablets. The company hopes the FDA will approve the drug for managing neuropathic pain related to diabetic peripheral neuropathy in adults. The FDA approved the drug for managing moderate to severe chronic pain in adults who require a continuous, around-the-clock opioid treatment.
Of the nearly 26 million Americans living with diabetes, about 60% to 70% of them have some form of neuropathy, of which diabetic peripheral neuropathy is the most common type, according to J&J. The condition causes pain or loss of feeling in the toes, feet, legs, hands and arms.
United Supermarkets to roll out FlavoRx’s Fillmaster Plus dispensing technology
LUBBOCK, Texas — Texas-based supermarket operator United Supermarkets has teamed up with FlavoRx to roll out the Fillmaster Plus dispensing technology at all of the chain’s pharmacies.
Fillmaster Plus is a pharmacy device that automates drug reconstitution. How it works: When a prescription bottle is scanned using the Fillmaster Plus, the unit displays the medication’s name, volume, strength and the amount of purified water it needs for reconstitution. This process reduces the risk of dispensing errors and reconstitution is completed in a matter of seconds, FlavoRx said.
"United Supermarkets is making a strong statement with its investment in the Fillmaster Plus," FlavoRx president and CEO Stuart Amos said. “It says a lot about the company’s commitment to improving not only the lives of its customers, but of its employees behind the counter as well."
Report: Catalyst Rx case study justifies Walgreens PBM network inclusion
ROCKVILLE, Md. — Catalyst Rx, the pharmacy benefits management subsidiary of Catalyst Health Solutions, on Friday took out a full-page ad in the Wall Street Journal touting the value of a Walgreens pharmacy to a large healthcare payer. Catalyst also released a case study touting that value, according to a DrugChannels.net report.
According to that case study, Walgreens achieved a generic utilization rate of 69% versus 67.7% for all other chains in the area, resulting in a cost-per-script savings of $3.30.
"Excluding Walgreens from the case study client pharmacy network would cause significant member disruption, create potential gaps in patient care and impact costs to the client, its employees, retirees and their dependents," Catalyst Rx stated. "As with all of our participating pharmacy partners, we recognize the services and the value delivered by Walgreens to its local community residents and are pleased to continue to include them in our network in 2012."
For a copy of the case study, click here.
Catalyst Rx in June completed its acquisition of Walgreens’ pharmacy benefit management subsidiary.